In this issue:
Sparsentan vs irbesartan for focal segmental glomerulosclerosis
Phase 2 trial of sibeprenlimab in patients with IgA nephropathy
Future burden of kidney disease in Australia based on different scenarios
Impact of finerenone-induced albuminuria reduction on CKD outcomes in type 2 diabetes
Efficacy and safety of aldosterone synthase inhibition ± empagliflozin for CKD
Bone marrow iron load and liver iron concentrations in dialysis-associated haemosiderosis
“Slow and low” tacrolimus dosing regimen after renal transplantation
Cost-effectiveness of school urinary screening for early detection of IgA nephropathy in Japan
Plasma-Lyte vs standard intravenous fluids in paediatric kidney transplant recipients
Enhancing parathyroid hormone measurements in patients with CKD
Please login below to download this issue (PDF)